Journal of Gerontological Nursing

Product News 

Product News

Abstract

A randomized, double-blind, placebo-controlled study published in BMC Medical Genetics has identified the genetic profile of Alzheimer’s disease (AD) patients who have a high probability of responding to Axona® (AC-1202), a prescription medical food product available at pharmacies nationwide.

In the study, variances in the DNA sequences associated with the genes responsible for producing insulin-degrading enzyme (IDE) and the pro-inflammatory cytokine interleukin-1beta (IL1B) were shown to be highly predictive for improvement in cognition among patients receiving Axona.

Other studies have shown a correlation between an increased risk for AD among carriers of the apolipoprotein E4 allele (APOE4), and Accera, Inc., the biotech company that markets Axona, has previously published its findings from a double-blind, placebo-controlled study showing that AD patients who were noncarriers of the APOE4 gene (APOE4(-)) experienced significant cognitive improvements in a 90-day trial of AC-1202. This additional analysis has shown that specific genotype combinations of E4(-), IDE, and IL1B produced additive improvements in cognitive performance.

AD patients who carried combinations of common variants in IDE, APOE, and IL1B showed as much as a 7-point increase in cognitive function as measured by the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADASCog), one of the most widely used scales for anti-dementia drugs in the United States. Changes in the ADAS-Cog scores of more than 3 to 4 points are generally recognized as being clinically meaningful. Since the specific variations in the genes for IDE and IL1B are commonly observed in the AD population, the number of patients who are likely to experience a heightened therapeutic benefit from Axona should be significant.

This result was particularly surprising because the majority of participants in the study were already taking one or more approved Alzheimer’s disease medications.

Axona, a medical food product taken once daily, overcomes disruptions in glucose metabolism by providing the brain with ketone bodies, an alternative fuel source that results in improved cognition.

The study is available for free at http://www.biomedcentral.com/1471-2350/12/137. More information about Axona can be accessed at http://www.about-axona.com.

Source.“Genetic Profile Identified for Alzheimer’s Patients Showing Heightened Response to Accera’s Breakthrough Product Axona®.” (2011, October 17). Retrieved January 30, 2012, from http://www.prnewswire.com/news-releases/genetic-profile-identifiedfor-alzheimers-patients-showing-heightened-response-to-acceras-breakthrough-product-axona-131979768.html.

TapeRelief has launched its proprietary formula for wound care and prevention of contact dermatitis from medical tape and bandages. Applied to the skin as a fast-drying cream, TapeRelief prevents irritation common to frequent users of bandages and tape by creating a topical barrier between the tape or bandage and the skin. The tape or bandage then adheres to the dried layer of TapeRelief, preventing any irritation from adhesive, moisture, and more. Additionally, TapeRelief includes healing and soothing ingredients such as organic oatmeal and tea tree oil to improve the underlying skin while it also protects.

For more information and request for a free sample, visit http://www.TapeRelief.com.

Source.“New TapeRelief Formula Provides Innovative Wound Care and Skin Protection.” (2012, January 18). Retrieved January 30, 2012, from http://www.globenewswire.com/newsroom/news.html?d=243044.

Study Identifies Genetic Profiles Most Receptive to AD Medical Food

A randomized, double-blind, placebo-controlled study published in BMC Medical Genetics has identified the genetic profile of Alzheimer’s disease (AD) patients who have a high probability of responding to Axona® (AC-1202), a prescription medical food product available at pharmacies nationwide.

In the study, variances in the DNA sequences associated with the genes responsible for producing insulin-degrading enzyme (IDE) and the pro-inflammatory cytokine interleukin-1beta (IL1B) were shown to be highly predictive for improvement in cognition among patients receiving Axona.

Other studies have shown a correlation between an increased risk for AD among carriers of the apolipoprotein E4 allele (APOE4), and Accera, Inc., the biotech company that markets Axona, has previously published its findings from a double-blind, placebo-controlled study showing that AD patients who were noncarriers of the APOE4 gene (APOE4(-)) experienced significant cognitive improvements in a 90-day trial of AC-1202. This additional analysis has shown that specific genotype combinations of E4(-), IDE, and IL1B produced additive improvements in cognitive performance.

AD patients who carried combinations of common variants in IDE, APOE, and IL1B showed as much as a 7-point increase in cognitive function as measured by the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADASCog), one of the most widely used scales for anti-dementia drugs in the United States. Changes in the ADAS-Cog scores of more than 3 to 4 points are generally recognized as being clinically meaningful. Since the specific variations in the genes for IDE and IL1B are commonly observed in the AD population, the number of patients who are likely to experience a heightened therapeutic benefit from Axona should be significant.

This result was particularly surprising because the majority of participants in the study were already taking one or more approved Alzheimer’s disease medications.

Axona, a medical food product taken once daily, overcomes disruptions in glucose metabolism by providing the brain with ketone bodies, an alternative fuel source that results in improved cognition.

The study is available for free at http://www.biomedcentral.com/1471-2350/12/137. More information about Axona can be accessed at http://www.about-axona.com.

Source.“Genetic Profile Identified for Alzheimer’s Patients Showing Heightened Response to Accera’s Breakthrough Product Axona®.” (2011, October 17). Retrieved January 30, 2012, from http://www.prnewswire.com/news-releases/genetic-profile-identifiedfor-alzheimers-patients-showing-heightened-response-to-acceras-breakthrough-product-axona-131979768.html.

Cream Prevents Skin Irritation from Bandages

TapeRelief has launched its proprietary formula for wound care and prevention of contact dermatitis from medical tape and bandages. Applied to the skin as a fast-drying cream, TapeRelief prevents irritation common to frequent users of bandages and tape by creating a topical barrier between the tape or bandage and the skin. The tape or bandage then adheres to the dried layer of TapeRelief, preventing any irritation from adhesive, moisture, and more. Additionally, TapeRelief includes healing and soothing ingredients such as organic oatmeal and tea tree oil to improve the underlying skin while it also protects.

For more information and request for a free sample, visit http://www.TapeRelief.com.

Source.“New TapeRelief Formula Provides Innovative Wound Care and Skin Protection.” (2012, January 18). Retrieved January 30, 2012, from http://www.globenewswire.com/newsroom/news.html?d=243044.

10.3928/00989134-20120215-01

Sign up to receive

Journal E-contents